| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2005;79:1840-1844
© 2005 The Society of Thoracic Surgeons
a Division of Thoracic Surgery, Cardiac and Thoracic Department, University of Pisa, Pisa, Italy
b Division of Pathology, Department of Oncology, University of Pisa, Pisa, Italy
Accepted for publication December 28, 2004.
* Address reprint requests to Dr Lucchi, Division of Thoracic Surgery, Cardiac and Thoracic Department, University of Pisa, Via Paradisa 2, Pisa 56124, Italy (E-mail: m.lucchi{at}med.unipi.it).
BACKGROUND: With the aim of evaluating the results of multidisciplinary approaches, we reviewed our experience in multimodality treatment of advanced stage (III and IVA) thymic tumors.
METHODS: From 1976 to 2003, 56 patients with Masaoka stage III and IVA thymic tumors underwent a multimodality treatment. Thirty-six patients underwent neoadjuvant chemotherapy, surgery, and postoperative radiotherapy; 20 patients were treated by primary surgery and postoperative radiotherapy (n = 12), chemotherapy (n = 1) or chemoradiotherapy (n = 7). The neoadjuvant or adjuvant chemotherapy consisted of three courses of cisplatin, epidoxorubicin, and etoposide every 3 weeks. Adjuvant radiotherapy consisted of 45 Gy for complete resections or 60 Gy for incomplete resections.
RESULTS: The preoperative diagnosis of invasive thymomas was performed in a total of 29 cases: 15 by mediastinotomy, 6 by video-assisted thoracoscopic surgery, and 8 by fine-needle aspiration. In 27 cases no diagnosis was available, but in most of them a thymus-related syndrome was present. Thirty-four patients are still alive (31 disease-free), and 22 have died (2 disease-free). Ten-year survival was 48% and 45.7% for stage III and IVA thymomas, respectively. The presence of myasthenia gravis (p = 0.04) and neoadjuvant chemotherapy (p = 0.004) affected survival significantly.
CONCLUSIONS: The multimodality treatment of stage III and IVA thymic tumors allows a good long-term outcome; the neoadjuvant chemotherapy improves the resectability rate and the survival of both stages of the disease.
This article has been cited by other articles:
|
|
 |
|
  S. Heyman and P. Van Schil Surgery for isolated pleural recurrence from thymoma Eur. J. Cardiothorac. Surg., September 1, 2008; 34(3): 707 - 708. [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-J. Cheng Videothoracoscopic Resection of Encapsulated Thymic Carcinoma: Retrospective Comparison of the Results Between Thoracoscopy and Open Methods Ann. Surg. Oncol., August 1, 2008; 15(8): 2235 - 2238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lucchi, F. Basolo, and A. Mussi Surgical treatment of pleural recurrence from thymoma Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 707 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Huang, G. J. Riely, K. E. Rosenzweig, and V. W. Rusch Multimodality Therapy for Locally Advanced Thymomas: State of the Art or Investigational Therapy? Ann. Thorac. Surg., February 1, 2008; 85(2): 365 - 367. [Full Text] [PDF]
|
|
|
|
|
|
C. D. Wright, N. C. Choi, J. C. Wain, D. J. Mathisen, T. J. Lynch, and P. Fidias Induction Chemoradiotherapy Followed by Resection for Locally Advanced Masaoka Stage III and IVA Thymic Tumors Ann. Thorac. Surg., February 1, 2008; 85(2): 385 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Huang, N. P. Rizk, W. D. Travis, V. E. Seshan, M. S. Bains, J. Dycoco, R. J. Downey, R. M. Flores, B. J. Park, and V. W. Rusch Feasibility of multimodality therapy including extended resections in stage IVA thymoma. J. Thorac. Cardiovasc. Surg., December 1, 2007; 134(6): 1477 - 1484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Maggi and E. Ruffini Invited commentary Ann. Thorac. Surg., June 1, 2005; 79(6): 1844 - 1844. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
